The FDA Utilizes the Rosetta Biosoftware Syllego(TM) System to Support Management of Genome-Wide Association Study Data Submitted Through the VXDS Program

SEATTLE--(BUSINESS WIRE)--Rosetta Biosoftware today announced that the U.S. Food and Drug Administration (FDA) will utilize the Rosetta Syllego™ system to meet its immediate need for a software solution to manage and analyze genotyping data used in genome-wide association (GWA) studies. Organizations are now beginning to submit genotyping data from GWA studies to the FDA through its Voluntary eXploratory Data Submission (VXDS) program. Research organizations conducting GWA studies have the potential to reveal genetic risk factors for diseases such as coronary artery disease, type 2 diabetes and other complex diseases.